---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062528"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:44:39.858567+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma appoints John Hohneker, M.D., to Board of Directors

## Summary
- John Hohneker, M.D., appointed to Board of Directors effective May 16, 2024 as Class II Director.
- Dr. Hohneker most recently served as President & CEO of Anokion SA, and previously led R&D at Forma Therapeutics.
- He held senior roles at Novartis for 14 years, including SVP and Global Head of Development, Immunology and Dermatology.
- Current board seats: Carisma Therapeutics (CARM), Curis (CRIS), Sonata Therapeutics, and Trishula Therapeutics.
- Received initial non-qualified stock option with fair value $352,500 vesting over three years; annual cash retainer $45,000.

## SEC filing metadata
- accession: 0001104659-24-062528
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465924062528/0001104659-24-062528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465924062528/tm2414720d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062528
- JSON: https://secwatch.observer/filing/0001104659-24-062528.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062528.txt

## Key facts
- Executive change
  John Hohneker, M.D. was appointed as Class II Director at ArriVent BioPharma, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1868279/000110465924062528/0001104659-24-062528-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.